The Integrated Care Board (local commissioners for weight management services in the area, also refered to as ICB) have informed us that following approval by National Institute for Health and Care Excellence (NICE) tirzepatide (Mounjaro®) will be available in the NHS for eligible patients who meet the strict, nationally set, criteria.
The current criteria is that patients are those with a Body Mass Index (BMI) of 40 or higher, and all five of the qualifying comorbidities (hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes) will be eligible for assessment to identify their suitability for Mounjaro. Anyone not meeting these criteria will not be eligible for assessment in the first year of the drug being available.
Please do not contact your GP; if you are eligible to be assessed you will be contacted over the coming months and invited to attend an appointment for assessment. Those with the greatest clinical need will be contacted first.
More information on local Weight Management services can be found on the Integrated Care System webpage please: Local Weight Management services Staffordshire and Stoke on Trent, Integrated Care System